New drug discovery, scientific IP development and clinical trials
Develop therapeutic treatments for different mental health conditions and neurodegenerative diseases


Our Second Mover Advantage & unique approach in conducting biotech drug discovery and development will differentiate us from other “psychedelic” companies in this space:

  • We are focused on the development of psychedelic drugs to prevent and treat neurodegenerative diseases such as Alzheimer’s, dementia, Parkinson’s, etc. Our peers are mainly focused on mood disorders, depression, PTSD, trauma. The neurodegenerative diseases could be treated with ongoing use of low-dose psychedelic drugs making it an ideal treatment model for big pharma.
  • We are focused on a novel development of a Personalized “Precision” Medicine Platform using AI technology capabilities to treat mood disorders such as depression and anxiety. Personalized dosage is essential to achieving positive results (void of negative side effects). Every individual is unique in their tolerance and reaction to psychedelic medicines and this is why we are taking this unique approach to developing medicines for mood disorders.